GlassScriptPhysician profile
Christopher Charles Wyckoff
NPI 1669649620
$9,726.26
in general payments reported to CMS, 2019-2025
41 companies · $3,004 in 2025
The $3,004 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $488 · 2021: $553 · 2022: $1,028 · 2023: $1,624 · 2024: $2,003 · 2025: $3,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554 · Consulting Fee: $1,950 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,553.75 |
| Consulting Fee | $1,950.00 |
| Education | $127.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,118.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,665.75 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Genzyme Corporation | $716.10 | 2019-2025 | |
| Amgen INC. | $472.65 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.35 | 2019-2024 | Ofev, Spiriva Respimat |
| Grifols USA, LLC | $371.64 | 2019-2024 | Prolastin-C Liquid |
| Insmed, INC. | $285.06 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $275.42 | 2019-2024 | Yupelri |
| Electromed, INC. | $233.04 | 2019-2025 | Smartvest |
| United Therapeutics Corporation | $232.58 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $194.59 | 2020-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $172.39 | 2019-2024 | Opsumit, Uptravi |
| Genentech USA, INC. | $149.29 | 2019-2023 | Xolair |
| Mallinckrodt Hospital Products INC. | $146.93 | 2023-2024 | Acthar |
| Shionogi INC | $133.35 | 2024-2025 | Fetroja |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wyckoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.